Literature DB >> 12212693

Cerebrovascular complication associated with pulmonary vein ablation.

Lai Chow Kok1, J Michael Mangrum, David E Haines, J Paul Mounsey.   

Abstract

INTRODUCTION: Radiofrequency (RF) ablation has become an established treatment modality for patients with paroxysmal atrial fibrillation (AF). A principal limitation of RF catheter ablation is the risk of thromboembolism. Stroke as a complication after ablation of triggers of AF has not been previously reported. METHODS AND
RESULTS: Fifty-six patients underwent RF ablation for a focal source of AF. Forty-nine patients (86%) had AF triggers in > or = 1 pulmonary vein. Mean procedure time was 227 +/- 74 minutes. Cerebrovascular event occurred in 3 (5%) patients, all >60 years old. Two of the three patients had a prior history of transient ischemic attacks.
CONCLUSION: The risk of stroke from RF ablation may be higher in paroxysmal AF patients with prior transient ischemic attack.

Entities:  

Mesh:

Year:  2002        PMID: 12212693     DOI: 10.1046/j.1540-8167.2002.00764.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  18 in total

1.  Transmembraneous irrigation of multipolar radiofrequency ablation catheters: induction of linear lesions encircling the pulmonary vein ostium without the risk of coagulum formation?

Authors:  Christian Weiss; Mark Stewart; Olaf Franzen; Thomas Rostock; Jan Becker; Jim R Skarda; Thomas Meinertz; Stephan Willems
Journal:  J Interv Card Electrophysiol       Date:  2004-06       Impact factor: 1.900

Review 2.  Clinical applications of intracardiac echocardiography in interventional procedures.

Authors:  M R M Jongbloed; M J Schalij; K Zeppenfeld; P V Oemrawsingh; E E van der Wall; J J Bax
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

3.  A novel highly articulated robotic surgical system for epicardial ablation.

Authors:  Takeyoshi Ota; Amir Degani; David Schwartzman; Brett Zubiate; Jeremy McGarvey; Howie Choset; Marco A Zenati
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2008

4.  Accessory left atrial diverticulae: contractile properties depicted with 64-slice cine-cardiac CT.

Authors:  Ronan P Killeen; Ronan Ryan; Aoife MacErlane; Ramon Martos; David Keane; Jonathan D Dodd
Journal:  Int J Cardiovasc Imaging       Date:  2009-09-19       Impact factor: 2.357

5.  Long-term single procedure efficacy of catheter ablation of atrial fibrillation.

Authors:  Aamir Cheema; Chandrasekhar R Vasamreddy; Darshan Dalal; Joseph E Marine; Jun Dong; Charles A Henrikson; David Spragg; Alan Cheng; Saman Nazarian; Sunil Sinha; Henry Halperin; Ronald Berger; Hugh Calkins
Journal:  J Interv Card Electrophysiol       Date:  2006-08-05       Impact factor: 1.900

Review 6.  Ablation of Atrial Fibrillation in the Elderly: Current Evidence and Evolving Trends.

Authors:  Suraj Kapa; Rupa Bala
Journal:  J Atr Fibrillation       Date:  2011-07-15

7.  Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation.

Authors:  Charles J Bruce; Paul A Friedman; Om Narayan; Thomas M Munger; Stephen C Hammill; Douglas L Packer; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2008-06-21       Impact factor: 1.900

8.  Percutaneous pulmonary vein cryoablation to treat atrial fibrillation.

Authors:  Tom Wong; Vias Markides; Nicholas S Peters; D Wyn Davies
Journal:  J Interv Card Electrophysiol       Date:  2004-10       Impact factor: 1.900

9.  Femoral vascular complications following catheter ablation of atrial fibrillation.

Authors:  Liza A Prudente; J Randall Moorman; Douglas Lake; Yuping Xiao; Heather Greebaum; J Michael Mangrum; John P DiMarco; John D Ferguson
Journal:  J Interv Card Electrophysiol       Date:  2009-04-22       Impact factor: 1.900

Review 10.  Atrial fibrillation: what are the targets for intervention?

Authors:  John M Miller; Jeffrey E Olgin; Mithilesh K Das
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.